Topic: Genetics

Scientists at Karolinska Institutet and Chinese hospitals treated 10 patients with congenital deafness or severe hearing loss. After a single injection, most patients regained some hearing within one month, and all showed clear improvement after six months.

In a breakthrough study, researchers have found that gene therapy can significantly improve hearing in people born with congenital deafness or severe hearing loss. The treatment involves targeting the OTOF gene, which is responsible for sending sound signals from the inner ear to the brain. When this gene is faulty, it prevents the body from producing enough of a protein called otoferlin, leading to deafness.

The study involved 10 patients between the ages of 1 and 24 who were treated at five hospitals in China. All participants had a genetic form of deafness linked to mutations in the OTOF gene. The therapy was given as a single injection through a membrane at the base of the cochlea, known as the round window.

The results were rapid and impressive. Most patients began to regain some hearing within one month, and all participants showed clear improvement after six months. On average, the level of sound they could detect improved from 106 decibels to 52.

Children showed the most dramatic responses, especially those between the ages of five and eight. One seven-year-old girl regained nearly full hearing and was able to have everyday conversations with her mother just four months after treatment.

The therapy was also well-tolerated, with the most common side effect being a decrease in neutrophils, a type of white blood cell. No serious adverse reactions were observed during the follow-up period of 6 to 12 months.

Why It Matters

This breakthrough has the potential to greatly improve the lives of children and adults born with congenital deafness or severe hearing loss. It also highlights the importance of gene therapy in treating genetic disorders.

Key Facts

• The study involved 10 patients between the ages of 1 and 24 who were treated at five hospitals in China.
• The therapy was given as a single injection through a membrane at the base of the cochlea, known as the round window.
• Most patients began to regain some hearing within one month, and all participants showed clear improvement after six months.
• Children showed the most dramatic responses, especially those between the ages of five and eight.
• The therapy was well-tolerated, with the most common side effect being a decrease in neutrophils, a type of white blood cell.

Key Terms

OTOF gene

A gene responsible for sending sound signals from the inner ear to the brain.

Implications

This breakthrough has the potential to greatly improve the lives of children and adults born with congenital deafness or severe hearing loss. It also highlights the importance of gene therapy in treating genetic disorders.